Type 2 diabetes significantly modulates the cardiovascular risk conferred by the PAI-1 - 675 4G/5G polymorphism in angiographied coronary patients

Clinica Chimica Acta

Volumn 396, Issue 1-2, 2008, Pages 18-22

  Saely, Christoph H ^a,b,c   Muendlein, Axel ^a,b   Vonbank, Alexander ^a   Sonderegger, Gudrun ^a   Aczel, Stefan ^a,b   Rein, Philipp ^a,b,c   Risch, Lorenz ^a   Drexel, Heinz ^a,b,c,d  

^a Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^b ACADEMIC TEACHING HOSPITAL FELDKIRCH   (Austria)

^c University for Human Sciences   (Liechtenstein)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Coronary atherosclerosis; Genetic polymorphism; Plasminogen activator inhibitor 1; Prospective study; Type 2 diabetes

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; SMOKING;

ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 50249178135     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.06.015     Document Type: Article

References (36)

1. Hamsten A., de Faire U., Walldius G., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2 (1987) 3-9
2. Smith A., Patterson C., Yarnell J., Rumley A., Ben Shlomo Y., and Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 112 (2005) 3080-3087
3. Hong Y., Pedersen N.L., Egberg N., and de Faire U. Moderate genetic influences on plasma levels of plasminogen activator inhibitor-1 and evidence of genetic and environmental influences shared by plasminogen activator inhibitor-1, triglycerides, and body mass index. Arterioscler Thromb Vasc Biol 17 (1997) 2776-2782
4. de Lange M., Snieder H., Ariens R.A., Spector T.D., and Grant P.J. The genetics of haemostasis: a twin study. Lancet 357 (2001) 101-105
5. Eriksson P., Kallin B., 't Hooft F.M., Bavenholm P., and Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 92 (1995) 1851-1855
6. Margaglione M., Cappucci G., Colaizzo D., et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 18 (1998) 152-156
7. Ossei-Gerning N., Mansfield M.W., Stickland M.H., Wilson I.J., and Grant P.J. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 17 (1997) 33-37
8. Ye S., Green F.R., Scarabin P.Y., et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost 74 (1995) 837-841
9. Panahloo A., Mohamed-Ali V., Lane A., Green F., Humphries S.E., and Yudkin J.S. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 44 (1995) 37-42
10. Sampaio M.F., Hirata M.H., Hirata R.D., et al. AMI is associated with polymorphisms in the NOS3 and FGB but not in PAI-1 genes in young adults. Clin Chim Acta 377 (2007) 154-162
11. Zak I., Balcerzyk A., Sarecka B., Niemiec P., Ciemniewski Z., and Dylag S. Contemporaneous carrier-state of two or three "proatherosclerotic" variants of APOE, ICAM1, PPARA and PAI-1 genes differentiate CAD patients from healthy individuals. Clin Chim Acta 362 (2005) 110-118
12. Ye Z., Liu E.H., Higgins J.P., et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 367 (2006) 651-658
13. Su S., Chen S., Zhao J., et al. Plasminogen activator inhibitor-1 gene: selection of tagging single nucleotide polymorphisms and association with coronary heart disease. Arterioscler Thromb Vasc Biol 26 (2006) 948-954
14. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 241 (1979) 2035-2038
15. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
16. Drexel H., Aczel S., Marte T., et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?. Diabetes Care 28 (2005) 101-107
17. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
18. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
19. Drexel H., Amann F.W., Beran J., et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 90 (1994) 2230-2235
20. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
21. Levey A.S., Greene T., Kusek J.W., and Beck G.J. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11 (2000) 157A
22. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
23. Mansfield M.W., Stickland M.H., and Grant P.J. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 74 (1995) 1032-1034
24. Nagi D.K., McCormack L.J., Mohamed-Ali V., Yudkin J.S., Knowler W.C., and Grant P.J. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care 20 (1997) 1304-1309
25. Petrovic D., Globocnik-Petrovic M., and Peterlin B. 4G4G genotype of PAI-1 gene promoter polymorphism is not associated with myocardial infarction in Caucasians with type-2 diabetes. Cardiology 100 (2003) 157-158
26. Lopes C., Dina C., Durand E., and Froguel P. PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia 46 (2003) 1284-1290
27. Wascher T.C., Sourij H., Roth M., and Dittrich P. Prevalence of pathological glucose metabolism in patients undergoing elective coronary angiography. Atherosclerosis 176 (2004) 419-421
28. Saely C.H., Koch L., Schmid F., et al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 29 (2006) 901-907
29. Grubic N., Stegnar M., Peternel P., Kaider A., and Binder B.R. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 84 (1996) 431-443
30. Torres-Carrillo N.M., Torres-Carrillo N., Vazquez-Del Mercado M., et al. The -844 G/A PAI-1 polymorphism is associated with mRNA expression in rheumatoid arthritis. Rheumatol Int 28 (2008) 355-360
31. Mansfield M.W., Stickland M.H., and Grant P.J. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 74 (1995) 842-847
32. Mertens I., Van der P.M., Corthouts B., et al. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 33 (2001) 602-607
33. Naran N.H., Chetty N., and Crowther N.J. The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity. Atherosclerosis 196 (2008) 155-163
34. Saely C.H., Koch L., Schmid F., et al. Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. Eur J Clin Invest 36 (2006) 91-97
35. Juhan-Vague I., Pyke S.D., Alessi M.C., Jespersen J., Haverkate F., and Thompson S.G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 94 (1996) 2057-2063
36. Bashir S.A., Duffy S.W., and Qizilbash N. Repeat measurement of case-control data: corrections for measurement error in a study of ischaemic stroke and haemostatic factors. Int J Epidemiol 26 (1997) 64-70